Filing Flows › Tango Therapeutics (TNGX) › Q2 2025 › vs Q2 2024
Tango Therapeutics (TNGX) Q2 2025 vs Q2 2024 (year over year)
Tango Therapeutics's revenue fell $16.7M (-84%) from $19.9M in Q2 2024 to $3.2M in Q2 2025.
Tango Therapeutics, Q2 2025: revenue $3.2M (-84% year over year), net loss $38.9M, operating cash flow −$36.5M. The chart draws each line against Q2 2024, the increases inside each band.
Every line
| Line | Q2 2025 | Q2 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $3.2M | $19.9M | −$16.7M | -84% |
| Other income, net | $2.1M | $4.1M | −$1.9M | -47% |
| Net loss | $38.9M | $25.6M | $13.3M | +52% |
| Costs & expenses | $44.2M | $49.5M | −$5.3M | -11% |
| Operating costs | $44.1M | $49.4M | −$5.3M | -11% |
| Income tax | $35K | $65K | −$30K | -46% |
| Research & development | $32.8M | $38.7M | −$5.8M | -15% |
| General & admin | $11.3M | $10.8M | $568K | +5% |
| Operating cash sources | $43.7M | $31.8M | $11.9M | +38% |
| Depreciation | $625K | $632K | −$7K | -1% |
| Share-based compensation | $6.6M | $7.5M | −$968K | -13% |
| Cash used in operations | $36.5M | $23.6M | $12.9M | +55% |
| Net loss absorbed | $38.9M | $25.6M | $13.3M | +52% |
| Working capital & other | $4.9M | $6.2M | −$1.4M | -22% |
Questions
How much did Tango Therapeutics's revenue grow year over year in Q2 2025?
Tango Therapeutics's revenue fell $16.7M (-84%) from $19.9M in Q2 2024 to $3.2M in Q2 2025.